Want to see RGNX full AI Analyst Report?
RGNX Stock Chart & Stats
$9.38
-$0.02(-0.21%)
At close: 4:00 PM EDT
$9.38
-$0.02(-0.21%)
Day’s Range― - ―
52-Week Range$5.46 - $16.19
Previous CloseN/A
Volume1.25M
Average Volume (3M)1.26M
Market Cap
$590.16M
Enterprise Value$779.85
Total Cash (Recent Filing)$105.52M
Total Debt (Recent Filing)$68.95M
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Nov 11, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.79
Shares Outstanding66,013,190
10 Day Avg. Volume1,613,321
30 Day Avg. Volume1,258,990
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$22.00Price Target Upside134.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.31
Revenue Forecast (FY)$168.21M
Bulls Say, Bears Say
Bulls Say
NAV Platform And Partnering ModelThe proprietary NAV platform gives REGENXBIO multiple ways to create value through internal development, licenses, collaborations, milestones, and potential royalties. This diversified model can expand the company’s reach beyond its own pipeline and provide strategic leverage as partners advance programs.
Late-stage Retinal Pipeline ProgressStarting a Phase IIb/III trial and triggering a substantial partner milestone demonstrate meaningful clinical and commercial progression in retinal disease. Advancement toward pivotal data and a potential single-dose treatment could strengthen the pipeline and support future partnering or product revenue.
Improved Funding CapacityThe equity financing adds substantial capital to support operations and the late-stage pipeline, extending resources for clinical execution and regulatory work. Greater liquidity can reduce immediate funding pressure while the company advances candidates toward milestones and potential commercialization.
Bears Say
Persistent UnprofitabilityLarge operating and net losses indicate that REGENXBIO has not yet achieved an economically self-sustaining business model. Continued negative margins leave results dependent on future commercialization, partnering proceeds, or additional financing rather than internally generated earnings.
Ongoing Cash BurnDeeply negative operating and free cash flow show that the company continues to consume cash while funding research and development. Persistent burn can require repeated capital raises or milestone inflows, limiting financial flexibility and increasing execution risk before products generate revenue.
RGX-121 Clinical HoldThe clinical hold is a material setback for a major program, delaying development and making near-term BLA resubmission unlikely. Although patients were reported stable and other programs are unaffected, the event reduces pipeline certainty and shifts resources toward alternative candidates.
RegenXBio News
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $5.46 and its highest was $16.19 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $590.16M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Nov 11, 2026 which is in 65 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Aug 06, 2026. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.079 by $0.351.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -1.21.
How many shares outstanding does RegenXBio have?
RegenXBio has 66,013,190 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of $0.43 in its last earnings report, beating expectations of $0.079. Following the earnings report the stock price went up 7.429%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (134.54% Upside)
$22.00 (134.54% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 83%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $949.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
RegenXBio
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
RGNX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a notably positive clinical and programmatic update: RGX-202 met its pivotal primary endpoint with high biomarker expression, demonstrated an unusually strong correlation between microdystrophin and functional benefit (>0.9), and showed encouraging interim safety and functional signals with plans for potential accelerated approval in 2027. Key operational and regulatory risks were acknowledged — chiefly the limited number of mature 12‑month functional datapoints so far, reliance on external controls (and FDA concern about bias), and the possibility that the agency could request randomized trials which would materially delay approval. Remaining uncertainties on long‑term durability and the logistical burden of the prophylaxis regimen were also discussed. Overall the clinical readout and pipeline progress meaningfully outweigh near‑term risks, but regulatory process and more mature datasets remain critical next milestones.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$22.00
▲(134.54% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
7.10% Insiders
13.64% Mutual Funds
11.73% Other Institutional Investors
54.13% Public Companies and
Individual Investors